Tuesday, May 19, 2026 at 4:30 PM Eastern / 1:30 PM Pacific
Speaker:
Deena Rodney, APRN
This program is for patients, caregivers, and the community to learn about generalized myasthenia gravis (gMG) and IMAAVY® clinical data, the treatment journey, and resources and support.
IMAAVY™ is a prescription medicine used to treat adults and children 12 years of age and older with a disease called generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive.
Selected Important Safety Information
IMAAVY® is not for everyone; only your healthcare provider can decide if it’s right for you. Do not use if you are allergic to IMAAVY®. Reactions have included angioedema and anaphylaxis. IMAAVY® is a prescription medicine that may cause serious side effects, including infections, allergic (hypersensitivity) reactions, and infusion-related reactions. People treated with IMAAVY® should not receive live vaccines. Please read the Important Safety Information and the Medication Guide for IMAAVY® to learn more about these and other risks associated with IMAAVY®. Discuss any questions you have with your healthcare provider.
Please see the full Prescribing Information and Medication Guide for IMAAVY®.
Sponsored by Johnson & Johnson
Register
After registering, you will receive a confirmation email containing information about joining the webinar.